Recruiting

Testing a new drug for difficult-to-treat blood cancers

Plain-English translation of NCT07082803 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Read our Lymphoma research guide →

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new medication called to see if it can help people whose lymphoma (a blood cancer) has come back or stopped responding to previous treatments. Researchers want to understand how safe the medication is, how your body processes it, and whether it can shrink tumors. You may receive the medication by itself or combined with other lymphoma treatments, depending on which group you join.

Current treatments don't work for everyone with relapsed or hard-to-treat lymphomas, and some people run out of options. This trial exists to see if this new treatment might help patients who haven't benefited from standard therapies.

Do you qualify?

You likely qualify if…

you have been diagnosed with one of several types of non-Hodgkin lymphoma that has relapsed or stopped responding to prior treatments
you have received at least 1–2 prior lines of therapy, depending on your lymphoma type
you have measurable disease that can be tracked on imaging
you are in good enough overall health to tolerate the study (ECOG performance status of 0 or 1)
you are at least 4 weeks past any CAR T-cell or other T-cell targeting therapy

You likely don't qualify if…

you have active lymphoma in your central nervous system (brain or spinal cord)
you have had a stem cell transplant very recently (within 60–90 days)
you have had major surgery or severe trauma within the past 4 weeks
you are pregnant or breastfeeding
you have a serious uncontrolled infection or medical condition that would make participating unsafe

What participation looks like

You will visit the study center regularly for clinic visits where you'll receive the medication and have blood tests and imaging to monitor your health and how your lymphoma responds. Depending on which treatment group you're assigned to, you may take the medication alone or in combination with other lymphoma drugs. The study team will closely watch for side effects and track how well the treatment works for you throughout your participation.

AI-generated summary from trial data · Jul 16, 2026 · Not medical advice

Trial locations(14 sites)

United States

Stanford Medicine Cancer Center, Palo Alto, California

The START Center for Cancer Care - Midwest, Grand Rapids, Michigan

Washington University School of Medicine, St Louis, Missouri

Memorial Sloan Kettering Cancer Center, New York, New York

Weill Cornell Medicine - New York Presbyterian Hospital, New York, New York